Advertisement

Rheumatology International

, Volume 38, Issue 4, pp 549–556 | Cite as

Guidelines for management of rheumatic diseases in developing countries from basics to real-world situation: relevance, need, and processes for development

  • Durga Prasanna Misra
  • Aman Sharma
  • Vikas Agarwal
Expert Opinion
  • 211 Downloads

Abstract

Guidelines or recommendations help to provide uniform standards in medical practice. The development of guidelines requires adherence to pre-defined norms prescribed by different international organizations such as the European League against Rheumatism (EULAR). We searched Pubmed and LILACS to identify published papers in five major rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathies, osteoarthritis, and scleroderma) from different countries based on their economic prosperity and could find a lack of published literature from most economically weaker regions. Similarly, published guidelines in these rheumatic diseases were sparse from Asia and Africa, which are economically developed to a lesser extent than other regions of the world. Considering differing economic realities driving patient care in different regions of the world, unique challenges in certain geographic areas such as musculoskeletal manifestations of infectious diseases like leprosy and tuberculosis, as well as distinct risk of malignancies and other comorbid conditions, National Rheumatology societies should work towards developing more guidelines for rheumatic diseases from regions such as Asia and Africa, while following strictly the prescribed norms for the same. With a paucity of guidelines for such regions currently, an alternative (although less preferable) suggestion would be that major international societies, whose guidelines are widely read and followed the world over, should consider inputs from experts from diverse regions of the world while developing these guidelines.

Keywords

Guidelines Recommendations Low income Lower-middle income Developing country Rheumatology 

Abbreviations

ACR

American College of Rheumatology

AGREE

Appraisal of Guidelines for Research and Evaluation

ALNN

Asian Lupus Nephritis Network

APLAR

Asia Pacific League against Rheumatism

bDMARDs

Biologic disease-modifying anti-rheumatic drugs

cDMARDS

Conventional disease-modifying anti-rheumatic drugs

CNI

Calcineurin inhibitors

ERA–EDTA

European Renal Association–European Dialysis and Transplant Association

EULAR

European League against Rheumatism

GRADE

Grading of recommendations, assessment, development and evaluations

GRADEpro

GRADE profiler

GDP

Gross domestic product

GNI

Gross national income

LILACS

Literatura Latino Americana em Ciências da Saúde

NICE

National Institute of Clinical Excellence

PADI

Peptidyl arginine deiminase

PICO

Patient intervention comparator outcome

PRISMA

Preferred reporting standards for systematic reviews and meta-analysis

PTPN22

Protein tyrosine phosphatase 22

SOP

Standard operating procedure

WHO

World Health Organization

Notes

Author contributions

The conception and design of the study, or acquisition of data, or analysis and interpretation of data—DPM, AS, VA. Drafting the article—DPM; revising it critically for important intellectual content—AS, VA. Final approval of the version to be submitted—DPM, AS, VA. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved—DPM, AS, VA.

Funding

No funding was received for this study.

Compliance with ethical standards

Conflict of interest

Durga Prasanna Misra declares that he has no conflict of interest, including no relationship with pharmaceutical companies. Aman Sharma declares that he has no conflict of interest, including no relationship with pharmaceutical companies. Vikas Agarwal declares that he has no conflict of interest, including no relationship with pharmaceutical companies.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

296_2018_3996_MOESM1_ESM.docx (105 kb)
Supplementary material 1 (DOCX 105 KB)

References

  1. 1.
    Bornmann L, Mutz R (2015) Growth rates of modern science: a bibliometric analysis based on the number of publications and cited references. J Assoc Inf Sci Technol 66:2215–2222CrossRefGoogle Scholar
  2. 2.
    Sciarra E (2012) The importance of practice guidelines in clinical care. Dimens Crit Care Nurs 31:84–85.  https://doi.org/10.1097/DCC.0b013e3182445f62 CrossRefPubMedGoogle Scholar
  3. 3.
    van der Heijde D, Aletaha D, Carmona L et al (2015) 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 74:8–13.  https://doi.org/10.1136/annrheumdis-2014-206350 CrossRefPubMedGoogle Scholar
  4. 4.
    Hanson D, Hoss BL, Wesorick B (2008) Evaluating the evidence: guidelines. AORN J 88:184–196.  https://doi.org/10.1016/j.aorn.2008.04.017 CrossRefPubMedGoogle Scholar
  5. 5.
    Cam KM, McKnight PE, Doctor JN (2002) The delphi method online: medical expert consensus via the internet. In: Proceedings of the AMIA symposium, pp. 990Google Scholar
  6. 6.
    WHO (2014) Handbook for guideline development 2nd Edition [Internet] http://apps.who.int/medicinedocs/documents/s22083en/s22083en.pdf. Accessed 21 Dec 2017
  7. 7.
    Developing NICE guidelines [Internet] https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview. Accessed on 21 Dec 2017
  8. 8.
    PRISMA Checklist [Internet] http://www.prisma-statement.org/documents/PRISMA2009checklist.doc. Accessed 6 Dec 2017
  9. 9.
    Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417.  https://doi.org/10.1007/s00296-011-1999-3 CrossRefPubMedGoogle Scholar
  10. 10.
    GRADEpro [Internet] http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. Accessed 21 Nov 2017
  11. 11.
    Gasparyan AY, Ayvazyan L, Akazhanov NA, Kitas GD (2013) Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors. Croat Med J 54:600–608.  https://doi.org/10.3325/cmj.2013.54.600 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    World Bank Country and Lending Groups [Internet] https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed 18 Dec 2017
  13. 13.
    Public health expenditure (percentage of GDP) [Internet] https://data.worldbank.org/indicator/SH.XPD.PUBL.ZS Accessed 21 Dec 2017
  14. 14.
    World population by continent [Internet] http://worldpopulationreview.com/continents/. Accessed 23 Dec 2017
  15. 15.
  16. 16.
    Healthcare in India [Internet] http://assets.ce.columbia.edu/pdf/actu/actu-india.pdf. Accessed 23 Dec 2017
  17. 17.
    Chauhan S, Wakhlu A, Agarwal V (2010) Arthritis in leprosy. Rheumatology 49:2237–2242.  https://doi.org/10.1093/rheumatology/keq264 CrossRefPubMedGoogle Scholar
  18. 18.
    Held MFG, Hoppe S, Laubscher M et al (2017) Epidemiology of musculoskeletal tuberculosis in an area with high disease prevalence. Asian Spine J 11:405–411.  https://doi.org/10.4184/asj.2017.11.3.405 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Thiberville SD, Boisson V, Gaudart J et al (2013) Chikungunya fever: a clinical and virological investigation of outpatients on Reunion Island, South-West Indian Ocean. PLoS Negl Trop Dis 7:e2004.  https://doi.org/10.1371/journal.pntd.0002004 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Jacob N, Jacob CO (2012) Genetics of rheumatoid arthritis: an impressionist perspective. Rheum Dis Clin N Am 38:243–257.  https://doi.org/10.1016/j.rdc.2012.05.001 CrossRefGoogle Scholar
  21. 21.
    Lau CS, Chia F, Harrison A et al (2015) APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 18:685–713.  https://doi.org/10.1111/1756-185x.12754 CrossRefPubMedGoogle Scholar
  22. 22.
    Smolen JS, Landewe R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977.  https://doi.org/10.1136/annrheumdis-2016-210715 CrossRefPubMedGoogle Scholar
  23. 23.
    Mok CC, Yap DY, Navarra SV et al (2013) Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis 16:625–636.  https://doi.org/10.1111/1756-185x.12212 CrossRefPubMedGoogle Scholar
  24. 24.
    Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782.  https://doi.org/10.1136/annrheumdis-2012-201940 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Misra DP, Agarwal V, Sharma A, Wakhlu A, Negi VS (2017) 2016 update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low/middle income countries? Ann Rheum Dis 76:e47.  https://doi.org/10.1136/annrheumdis-2017-211446 CrossRefPubMedGoogle Scholar
  26. 26.
    Hannah J, Casian A, D’Cruz D (2016) Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun Rev 15:93–101.  https://doi.org/10.1016/j.autrev.2015.09.006 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical ImmunologySanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)LucknowIndia
  2. 2.Clinical Immunology and Rheumatology Services, Department of Internal MedicinePostgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia

Personalised recommendations